Evidence map›Paper›PMID 40407362›Full record

ReviewNutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition2025

Global prevalence of short bowel syndrome-associated intestinal failure in adults and children: A targeted literature review and analysis.

Bilal Khokhar, Vivek Pathania, Pradeep Nazarey, Narendra Parihar

Abstract readReview
In one paragraph

Review in Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Global prevalence of short bowel syndrome-associated intestinal failure in adults and children: A targeted literature review and analysis.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2025
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bilal KhokharTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0003-0143-1390
Vivek PathaniaClarivate, Noida, India.
Pradeep NazareyTakeda Pharmaceuticals U.S.A., Inc., Cambridge, Massachusetts, USA.
Narendra PariharClarivate, Philadelphia, Pennsylvania, USA.

Funding

This study was sponsored by Takeda Pharmaceuticals U.S.A., Inc., Medical writing assistance was provided by Liv Hayward, PhD, of PharmaGenesis Cardiff, Cardiff, UK, and was funded by Takeda Pharmaceuticals U.S.A., Inc., in accordance with Good Publication Practice (GPP 2022) guidelines (www.ismpp.org/gpp-2022)
6 · The paper itself

Abstract

Short bowel syndrome-associated intestinal failure (SBS-IF) is a rare disease caused by loss of function of the intestinal surface area and the subsequent inability to maintain nutrient and fluid balance on a normal diet, which results in the need for parenteral nutrition (PN) and/or intravenous fluids. There is a scarcity of literature regarding the prevalence of SBS-IF and challenges in estimating prevalence. A targeted literature review was conducted to generate prevalence estimates for SBS-IF, primarily defined by the requirement for home PN (HPN), in adults and children across multiple geographies. Country-specific estimates of HPN prevalence and the proportion of HPN cases associated with SBS were obtained from the literature and used to inform SBS-IF prevalence estimates. Adults were defined as those aged ≥18 years and children as those aged 0-17 years, except in Japan, where adults were those aged ≥15 years and children were aged 0-14 years. In total, 15 studies were included and were used to estimate and extrapolate prevalence across 61 countries for the years 2020-2030. The estimated prevalences of diagnosed SBS-IF in the general population in 2024 ranged from 0.12 to 2.74 per 100,000 in adults and 0.09 to 1.67 per 100,000 in children. Prevalence estimates were generally lower in countries with a lower average income. This study provides up-to-date insights into the overall global and country-by-country prevalence of SBS-IF and in defined cohorts of adults and children, addressing important gaps in the current literature.

Indexed as

Global HealthIntestinal FailureShort Bowel SyndromeAdolescentAdultChildChild, PreschoolHumansInfantInfant, NewbornMaleParenteral NutritionParenteral Nutrition, HomePrevalenceYoung Adultepidemiologyhome parenteral nutritionprevalenceshort bowel syndrome–associated intestinal failure

Identifiers

PMID40407362
PMCPMC12450332

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.